Literature DB >> 1724917

Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

R W Stephens1, H Tapiovaara, T Reisberg, J Bizik, A Vaheri.   

Abstract

Human RC2A myelomonocytic leukemia cells are able to activate the prourokinase (pro-u-PA) they secrete so that active u-PA is present both in serum-free conditioned medium from these cells, as well as on the cell surface. When the cells are grown in serum-containing medium, no u-PA activity can be found in the medium but active u-PA is found bound to the cell surface where it can generate bound plasmin. This distribution of u-PA activity was shown to be, first, the net result of slow inactivation of free active u-PA by serum inhibitor(s) and simultaneous rapid uptake of u-PA onto the cell surface. Binding to cells was at least six times faster than inactivation by 10% serum. The principal serum inhibitor of u-PA was identified as alpha 2-macroglobulin (alpha 2M), and prior inactivation of u-PA by purified human alpha 2M was also shown to prevent uptake of u-PA activity onto cells. Second, although endogenous u-PA could form covalent complexes with purified alpha 2M in the culture medium of RC2A cells, covalent alpha 2M complexes were not formed by u-PA on the cell surface; the u-PA taken up in this compartment was protected against alpha 2M inhibition. u-PA anchored to plastic surfaces via monoclonal antibodies to the amino-terminal region of u-PA was also protected against alpha 2M, suggesting that the protection of cell surface u-PA results from a steric effect. These results provide evidence as to how the active u-PA produced by leukemia cells can contribute to proteolytic activity on their cell surface in the presence of serum inhibitors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724917      PMCID: PMC361905          DOI: 10.1091/mbc.2.12.1057

Source DB:  PubMed          Journal:  Cell Regul        ISSN: 1044-2030


  41 in total

Review 1.  Plasminogen activator inhibitors: hormonally regulated serpins.

Authors:  P A Andreasen; B Georg; L R Lund; A Riccio; S N Stacey
Journal:  Mol Cell Endocrinol       Date:  1990-01-02       Impact factor: 4.102

2.  Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1.

Authors:  G Brunner; M M Simon; M D Kramer
Journal:  FEBS Lett       Date:  1990-01-15       Impact factor: 4.124

3.  Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.

Authors:  V J Hearing; L W Law; A Corti; E Appella; F Blasi
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

4.  Receptor for plasmin on human carcinoma cells.

Authors:  P Burtin; M C Fondaneche
Journal:  J Natl Cancer Inst       Date:  1988-07-20       Impact factor: 13.506

5.  Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators.

Authors:  J P Golder; R W Stephens
Journal:  Eur J Biochem       Date:  1983-11-15

6.  Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.

Authors:  R Stephens; R Alitalo; H Tapiovaara; A Vaheri
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

7.  Complex-formation and inhibition of urokinase by blood plasma proteins.

Authors:  E K Waller; W D Schleuning; E Reich
Journal:  Biochem J       Date:  1983-10-01       Impact factor: 3.857

8.  The inhibition of high and low molecular weight urokinase in plasma.

Authors:  G Murano; D Aronson; L Williams; L Brown
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

9.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

Authors:  A L Roldan; M V Cubellis; M T Masucci; N Behrendt; L R Lund; K Danø; E Appella; F Blasi
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  A study of proteases and protease-inhibitor complexes in biological fluids.

Authors:  A Granelli-Piperno; E Reich
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  1 in total

1.  Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.

Authors:  F O Akenami; V Sirén; M Koskiniemi; M A Siimes; H Teräväinen; A Vaheri
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.